Stay updated with breaking news from David Ricks. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Eli Lilly's CEO David Ricks told Reuters on Wednesday that the U.S. drugmaker expects to launch its obesity drug in Indian market as early as next year. ...
Eli Lilly plans to launch its obesity drug, tirzepatide, in India next year. The drug, also known as Mounjaro for diabetes and Zepbound for weight-loss in the U.S., may see authorized generic versions. CEO David Ricks emphasized the need for India to enhance patent protection and eliminate redundant policies to attract global drugmaker investments.
When a rally ends, it is often followed by a few quiet sessions. Yesterday, global indices remained within a small range, resulting in a few shades of red and green, but without excess. Investors are... -February 28, 2024 at 09:42 am EST - MarketScreener
Eli Lilly plans to launch its diabetes and obesity drug, Mounjaro, in India next year. The drug contains tirzepatide and is sold as Zepbound in the US. The global market for GLP-1 receptor agonists, including Mounjaro, Wegovy, and Ozempic, is expected to reach $100 billion by the end of the decade. Lilly's drugs as well as Danish rival Novo Nordisk's in-demand Wegovy and Ozempic are therapies known as GLP-1 receptor agonists, which were developed to control blood sugar in patients with type 2 diabetes.
Eli Lilly's CEO, David Ricks, outlines plans to launch the obesity drug Tirzepatide in India next year, presenting opportunities amid competition from Novo Nordisk. Bristol Myers Squibb expands its R&D footprint, eyeing India as a pivotal hub for innovation and clinical trials.